{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:22:26Z","timestamp":1793830946541,"version":"4.6.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008252","name":"Universit\u00e0 degli Studi di Udine","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008252","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>In 2024, two randomized controlled trials (RCTs) were published, providing new high-quality evidence on HIPEC in epithelial ovarian cancer (EOC). Updating data on progression-free survival (PFS) and adverse events could offer a clearer understanding of the benefits and risks of HIPEC combined with cytoreductive surgery (CRS), with or without prior neoadjuvant chemotherapy (NACT).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and Methods<\/jats:title>\n            <jats:p>An electronic search was conducted using PubMed, Web of Science, EBSCO, and CENTRAL up to 23 November 2024. We only included RCTs reporting PFS and adverse events of interval or secondary CRS, with or without HIPEC, in newly diagnosed or recurrent EOC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The meta-analysis included six RCTs. The addition of HIPEC to surgery significantly improved PFS in patients with newly diagnosed advanced-stage EOC who received NACT (HR 0.59; 95% CI 0.39\u20130.88; <jats:italic>p<\/jats:italic> = 0.01). No significant difference in PFS was observed between secondary CRS plus HIPEC and CRS alone in recurrent ovarian cancer without prior NACT (HR 1.22; 95% CI 0.82\u20131.83; <jats:italic>p<\/jats:italic> = 0.32). Regarding adverse events, a decrease in platelet count of any grade was more frequent in the HIPEC group (<jats:italic>p<\/jats:italic> = 0.03). The overall risk of acute kidney failure (AKF) was 10.6%, with a significantly higher incidence compared with CRS alone (<jats:italic>p<\/jats:italic> = 0.003).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The addition of HIPEC to CRS significantly improved PFS compared with surgery alone in patients with advanced EOC who received NACT. However, the treatment was associated with a higher incidence of AKF, which occurred in 10.6% of patients who underwent HIPEC.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1245\/s10434-025-16979-6","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T21:15:11Z","timestamp":1738703711000},"page":"3648-3659","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Cytoreductive Surgery Plus HIPEC in Recurrent or Newly Diagnosed Advanced Epithelial Ovarian Cancer: a Meta-analysis"],"prefix":"10.1245","volume":"32","author":[{"given":"C.","family":"Taliento","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Restaino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Arcieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Scutiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Greco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2424-2691","authenticated-orcid":false,"given":"G.","family":"Vizzielli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,4]]},"reference":[{"issue":"3","key":"16979_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA A Cancer J Clin."},{"issue":"1","key":"16979_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA A Cancer J Clin. 2022;72(1):7\u201333. https:\/\/doi.org\/10.3322\/caac.21708.","journal-title":"CA A Cancer J Clin."},{"key":"16979_CR3","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","volume":"335","author":"DS Alberts","year":"1996","unstructured":"Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996;335:1950\u20135.","journal-title":"N Engl J Med."},{"key":"16979_CR4","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"M Markman","year":"2001","unstructured":"Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19:1001\u20137.","journal-title":"J Clin Oncol."},{"issue":"6","key":"16979_CR5","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1053\/ctrv.2001.0232","volume":"27","author":"AJ Witkamp","year":"2001","unstructured":"Witkamp AJ, de Bree E, Van Goethem R, Zoetmulder FA. Rationale and techniques of intra-operative hyperthermic intraperitoneal chemotherapy. Cancer Treat Rev. 2001;27(6):365\u201374. https:\/\/doi.org\/10.1053\/ctrv.2001.0232. (PMID: 11908929).","journal-title":"Cancer Treat Rev."},{"issue":"1","key":"16979_CR6","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1056\/NEJMoa052985","volume":"354","author":"DK Armstrong","year":"2006","unstructured":"Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34\u201343. https:\/\/doi.org\/10.1056\/NEJMoa052985. (PMID: 16394300).","journal-title":"N Engl J Med."},{"issue":"3","key":"16979_CR7","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1056\/NEJMoa1708618","volume":"378","author":"WJ Van Driel","year":"2018","unstructured":"Van Driel WJ, Koole SN, Sikorska, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378(3):230\u201340. https:\/\/doi.org\/10.1056\/NEJMoa1708618. (PMID: 29342393).","journal-title":"N Engl J Med"},{"issue":"Suppl 6","key":"16979_CR8","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1093\/annonc\/mdt333","volume":"24","author":"JA Ledermann","year":"2013","unstructured":"Ledermann JA, Raja FA, Fotopoulou C, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):24\u201332. https:\/\/doi.org\/10.1093\/annonc\/mdt333.","journal-title":"Ann Oncol."},{"issue":"125 Suppl 24","key":"16979_CR9","doi-asserted-by":"publisher","first-page":"4594","DOI":"10.1002\/cncr.32496","volume":"15","author":"I Vergote","year":"2019","unstructured":"Vergote I, Harter P, Chiva L. Hyperthermic intraperitoneal chemotherapy does not improve survival in advanced ovarian cancer. Cancer. 2019;15(125 Suppl 24):4594\u20137. https:\/\/doi.org\/10.1002\/cncr.32496. (PMID: 31967685).","journal-title":"Cancer."},{"issue":"2","key":"16979_CR10","doi-asserted-by":"publisher","first-page":"258","DOI":"10.3390\/jpm13020258.PMID:36836494;PMCID:PMC9960788","volume":"13","author":"M Llueca","year":"2023","unstructured":"Llueca M, Iba\u00f1ez MV, Climent MT, et al. Effectiveness of hyperthermic intraperitoneal chemotherapy associated with cytoreductive surgery in the treatment of advanced ovarian cancer: systematic review and meta-analysis. J Pers Med. 2023;13(2):258. https:\/\/doi.org\/10.3390\/jpm13020258.PMID:36836494;PMCID:PMC9960788.","journal-title":"J Pers Med."},{"issue":"1","key":"16979_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/ijgc-2023-004658","volume":"34","author":"B Navarro Santana","year":"2024","unstructured":"Navarro Santana B, Garcia-Torralba E, Viveros-Carre\u00f1o D, et al. Complications of HIPEC for ovarian cancer surgery: evaluation over two time periods. Int J Gynecol Cancer. 2024;34(1):1\u20139. https:\/\/doi.org\/10.1136\/ijgc-2023-004658. (PMID: 37669829).","journal-title":"Int J Gynecol Cancer."},{"key":"16979_CR12","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1136\/ijgc-2018-000099","volume":"29","author":"MA Angeles","year":"2019","unstructured":"Angeles MA, Quenet F, Vieille P, et al. Predictive risk factors of acute kidney injury after cytoreductive surgery and cisplatin-based hyperthermic intra-peritoneal chemotherapy for ovarian peritoneal carcinomatosis. Int J Gynecol Cancer. 2019;29:382\u201391.","journal-title":"Int J Gynecol Cancer."},{"key":"16979_CR13","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1080\/02656736.2017.1293304","volume":"33","author":"EI-L Sin","year":"2017","unstructured":"Sin EI-L, Chia CS, Tan GHC, et al. Acute kidney injury in ovarian cancer patients undergoing cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. Int J Hyperth. 2017;33:690\u20135.","journal-title":"Int J Hyperth."},{"key":"16979_CR14","doi-asserted-by":"publisher","unstructured":"Classe JM, Meeus P, Hudry D, et al. Hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer (CHIPOR): a randomised, open-label, phase 3 trial. Lancet Oncol. 2024 Nov 13:S1470-2045(24)00531-X. https:\/\/doi.org\/10.1016\/S1470-2045(24)00531-X. Epub ahead of print. PMID: 39549720.","DOI":"10.1016\/S1470-2045(24)00531-X"},{"key":"16979_CR15","doi-asserted-by":"publisher","unstructured":"Fagotti A, Costantini B, Fanfani F, et al. Hyperthermic intraperitoneal chemotherapy in platinum-sensitive recurrent ovarian cancer: a randomized trial on survival evaluation (HORSE; MITO-18). J Clin Oncol. 2024 Nov 21:JCO2400686. https:\/\/doi.org\/10.1200\/JCO.24.00686. Epub ahead of print. PMID: 39571127.","DOI":"10.1200\/JCO.24.00686"},{"issue":"5","key":"16979_CR16","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/jamasurg.2022.0143.PMID:35262624;PMCID:PMC8908225","volume":"157","author":"MC Lim","year":"2022","unstructured":"Lim MC, Chang SJ, Park B, et al. Survival after hyperthermic intraperitoneal chemotherapy and primary or interval cytoreductive surgery in ovarian cancer: a randomized clinical trial. JAMA Surg. 2022;157(5):374\u201383. https:\/\/doi.org\/10.1001\/jamasurg.2022.0143.PMID:35262624;PMCID:PMC8908225.","journal-title":"JAMA Surg."},{"key":"16979_CR17","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ejogrb.2014.05.018","volume":"179C","author":"PA Cascales-Campos","year":"2014","unstructured":"Cascales-Campos PA, Gil J, Gil E, et al. Treatment of microscopic disease with hyperthermic intraoperative intraperitoneal chemotherapy after complete cytoreduction improves disease-free survival in patients with stage IIIC\/IV ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 2014;179C:88\u201393.","journal-title":"Eur J Obstet Gynecol Reprod Biol."},{"key":"16979_CR18","doi-asserted-by":"publisher","unstructured":"Zivanovic O, Chi DS, Zhou Q et al. 2021 Secondary cytoreduction and carboplatin hyperthermic intraperitoneal chemotherapy for platinum-sensitive recurrent ovarian cancer: an MSK team ovary phase II study. J Clin Oncol. 39(23):2594-2604. https:\/\/doi.org\/10.1200\/JCO.21.00605. Epub 2021 May 21. PMID: 34019431; PMCID: PMC8330970.","DOI":"10.1200\/JCO.21.00605"},{"issue":"372","key":"16979_CR19","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71.PMID:33782057;PMCID:PMC8005924","volume":"29","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;29(372):n71. https:\/\/doi.org\/10.1136\/bmj.n71.PMID:33782057;PMCID:PMC8005924.","journal-title":"BMJ."},{"issue":"5","key":"16979_CR20","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1245\/s10434-014-4157-9","volume":"22","author":"J Spiliotis","year":"2015","unstructured":"Spiliotis J, Halkia E, Lianos E, et al. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol. 2015;22(5):1570\u20135. https:\/\/doi.org\/10.1245\/s10434-014-4157-9. (Epub 2014 Nov 13 PMID: 25391263).","journal-title":"Ann Surg Oncol."},{"key":"16979_CR21","doi-asserted-by":"publisher","unstructured":"Filis P, Mauri D, Markozannes G, Tolia M, Filis N, Tsilidis K. Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer: a systematic review and meta-analysis of randomized trials. ESMO Open. 2022 Oct;7(5):100586. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100586. Epub 2022 Sep 16. PMID: 36116421; PMCID: PMC9588894.","DOI":"10.1016\/j.esmoop.2022.100586"},{"key":"16979_CR22","doi-asserted-by":"publisher","unstructured":"Oh GS, Kim HJ, Shen A, et al. Cisplatin-induced kidney dysfunction and perspectives on improving treatment strategies. Electrolyte Blood Press. 2014 ;12(2):55-65. https:\/\/doi.org\/10.5049\/EBP.2014.12.2.55. Epub 2014 Dec 31. PMID: 25606044; PMCID: PMC4297704.","DOI":"10.5049\/EBP.2014.12.2.55"},{"issue":"14","key":"16979_CR23","doi-asserted-by":"publisher","first-page":"1094834","DOI":"10.3389\/fphar.2023.1094834.PMID:36969856;PMCID:PMC10036049","volume":"9","author":"C Jian","year":"2023","unstructured":"Jian C, Mou H, Zhang Y, et al. Survival and complications of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in patients with intra-abdominal malignancies: a meta-analysis of randomized controlled trials. Front Pharmacol. 2023;9(14):1094834. https:\/\/doi.org\/10.3389\/fphar.2023.1094834.PMID:36969856;PMCID:PMC10036049.","journal-title":"Front Pharmacol."},{"issue":"12","key":"16979_CR24","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1016\/j.ejso.2013.09.030","volume":"39","author":"N Bakrin","year":"2013","unstructured":"Bakrin N, Bereder JM, Decullier E, et al. FROGHI (FRench Oncologic and Gynecologic HIPEC) Group. Peritoneal carcinomatosis treat- ed with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients. Eur J Surg Oncol. 2013;39(12):1435\u201343.","journal-title":"Eur J Surg Oncol."},{"key":"16979_CR25","doi-asserted-by":"publisher","unstructured":"Koole S, van Stein R, Sikorska K, Barton D, Perrin L, Brennan D, Zivanovic O, Mosgaard BJ, Fagotti A, Colombo PE, Sonke G, Driel WJV; OVHIPEC-2 Steering Committee and the Dutch OVHIPEC group. Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial. Int J Gynecol Cancer. 2020 Jun;30(6):888-892. https:\/\/doi.org\/10.1136\/ijgc-2020-001231. Epub 2020 Mar 23. PMID: 32205449; PMCID: PMC8202725.","DOI":"10.1136\/ijgc-2020-001231"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-16979-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-16979-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-16979-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T06:26:34Z","timestamp":1744093594000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-16979-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,4]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["16979"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-16979-6","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,4]]},"assertion":[{"value":"20 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}